Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 4/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.36 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PTGFR | P43088 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23395579 | 0.85 | NPC1 (0.41) | LPAR1ALDH1A1HPGD | |
| SCHEMBL21735625 | 0.84 | LPAR1 (0.45) | LPAR1ALDH1A1HPGD | |
| SCHEMBL23395540 | 0.81 | KCNK3 (0.46) | KCNK3KCNK9EPHX2ALDH1A1HPGD | |
| SCHEMBL14720336 | 0.78 | APLNR (0.47) | ALDH1A1 | |
| SCHEMBL27757778 | 0.77 | HRH4 (0.42) | ALPLMAOAMAOBKCNK3KCNK9 | |
| SCHEMBL5757330 | 0.77 | ALPL (0.41) | ALPLMAOAMAOBKCNK3KCNK9 | |
| SCHEMBL12868653 | 0.76 | HRH4 (0.43) | ALPLMAOAMAOBKCNK3KCNK9 | |
| SCHEMBL31266265 | 0.75 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL18103273 | 0.75 | MAPK1 (0.43) | ALDH1A1HPGD | |
| SCHEMBL15766202 | 0.74 | NR4A2 (0.46) | ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753387-B2 | Compounds for optically active devices | Johnson & Johnson Surgical Vision, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753387-B2 | Compounds for optically active devices | Johnson & Johnson Surgical Vision, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| EP-3889135-B1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2023-08-02 | — | — | EP | disclosed |
| EP-3889135-A1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3583092-B1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2021-05-26 | — | — | EP | disclosed |
| US-11014900-B2 | Hydrophilic compounds for optically active devices | MERCK PATENT GMBH (DE) | 2021-05-25 | — | — | US | disclosed |
| US-11014901-B2 | Hydrophobic compounds for optically active devices | MERCK PATENT GMBH (DE) | 2021-05-25 | — | — | US | disclosed |
| EP-3583098-B9 | HYDROPHILIC COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2021-05-12 | — | — | EP | disclosed |
| EP-3583091-B1 | HYDROPHOBIC COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2020-11-04 | — | — | EP | disclosed |
| EP-3583098-B1 | HYDROPHILIC COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2020-10-28 | — | — | EP | disclosed |
| US-20200231559-A1 | HYDROPHILIC COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2020-07-23 | — | — | US | disclosed |
| US-20200055833-A1 | HYDROPHOBIC COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055833-A1 | HYDROPHOBIC COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | UACA, CRYZ, TRPA1 | ALPL 3459/4885MAOA 2922/4885MAOB 3207/4885 |
| US-11753387-B2 | Compounds for optically active devices | PDE6C, PDE6A, PDE6D | ALPL 1184/4885MAOA 257/4885MAOB 372/4885 |
| US-11014901-B2 | Hydrophobic compounds for optically active devices | UACA, CRYZ, TRPA1 | ALPL 3459/4885MAOA 2922/4885MAOB 3207/4885 |
| US-20200231559-A1 | HYDROPHILIC COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | AQP1, AQP3, AQP4 | ALPL 2045/4885MAOA 2432/4885MAOB 2735/4885 |
| US-11014900-B2 | Hydrophilic compounds for optically active devices | AQP1, AQP3, AQP4 | ALPL 2045/4885MAOA 2432/4885MAOB 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.